These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Time course of distant effects of local injections of botulinum toxin. Garner CG; Straube A; Witt TN; Gasser T; Oertel WH Mov Disord; 1993; 8(1):33-7. PubMed ID: 8380486 [TBL] [Abstract][Full Text] [Related]
26. Costs of treating dystonias and hemifacial spasm with botulinum toxin A. Dodel RC; Kirchner A; Koehne-Volland R; Künig G; Ceballos-Baumann A; Naumann M; Brashear A; Richter HP; Szucs TD; Oertel WH Pharmacoeconomics; 1997 Dec; 12(6):695-706. PubMed ID: 10175981 [TBL] [Abstract][Full Text] [Related]
27. Response to botulinum toxin F in seronegative botulinum toxin A--resistant patients. Greene PE; Fahn S Mov Disord; 1996 Mar; 11(2):181-4. PubMed ID: 8684389 [TBL] [Abstract][Full Text] [Related]
28. Severe tongue protrusion dystonia: clinical syndromes and possible treatment. Schneider SA; Aggarwal A; Bhatt M; Dupont E; Tisch S; Limousin P; Lee P; Quinn N; Bhatia KP Neurology; 2006 Sep; 67(6):940-3. PubMed ID: 17000958 [TBL] [Abstract][Full Text] [Related]
29. Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years. Mauriello JA; Dhillon S; Leone T; Pakeman B; Mostafavi R; Yepez MC Br J Ophthalmol; 1996 Dec; 80(12):1073-6. PubMed ID: 9059273 [TBL] [Abstract][Full Text] [Related]
30. Use of botulinum toxin in Meige's disease. Maurri S; Brogelli S; Alfieri G; Barontini F Riv Neurol; 1988; 58(6):245-8. PubMed ID: 3247565 [TBL] [Abstract][Full Text] [Related]
31. Effect of treatment with botulinum toxin on neurogenic blepharospasm. Elston JS; Russell RW Br Med J (Clin Res Ed); 1985 Jun; 290(6485):1857-9. PubMed ID: 3924284 [TBL] [Abstract][Full Text] [Related]
32. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome. Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393 [TBL] [Abstract][Full Text] [Related]
33. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Van den Bergh P; Francart J; Mourin S; Kollmann P; Laterre EC Muscle Nerve; 1995 Jul; 18(7):720-9. PubMed ID: 7783762 [TBL] [Abstract][Full Text] [Related]